【No.】LIC002A 【Name】 Lenti-EF1a-CD19(FMC63)-2nd-CAR(CD28)-EGFRt
【Plasmid resistance】Amp 【Target】CD19
【Activation signal】4-1BB/CD3(Zeta) 【Packing specifications】4μg/tube

The proliferation and differentiation of lymphocytes varies with different concentrations of different antigens. The ability of B cells to respond to various antigens in a specific and sensitive manner is achieved through the use of low-affinity antigen receptors. The CD19 protein assembles with the B lymphocyte receptor to lower the threshold of antigen receptor-dependent stimulation. CD19 is expressed on follicular dendritic cells and B cells. The expression of CD19 runs through the entire development process of B cells, but it is not expressed on the surface of mature plasma cell membranes. Since CD19 is a marker of B cells, CAR-T targeting CD19 has shown shocking efficacy in the treatment of malignant B lymphocyte tumors. CAR-T constructed with FMC63 antibody (targeting CD19 murine monoclonal antibody) sequence has become the world's first CAR-T cell drug to be marketed . This product is a second-generation CAR lentiviral expression vector targeting CD19 with FMC63 as the scFv sequence.

Product name: Lenti-EF1a-CD19-2nd-CAR

Promoter: EF1a [1]

Intracellular co-activation signal: CD28/CD3Zata

Resistance gene: Amp

Tag: EGFRt [2]


1. Compared with the CMV promoter, EF1a can be continuously expressed in immune cells, so it can significantly extend the expression of CAR in T cells.

2. EGFRt intercepts domain III and domain IV of wild-type EGFR. This truncated EGFRt has no intracellular signal and will not transmit other signals to T cells . At the same time, these two domains are cetuximab Recognizing the epitope and expressing the epitope on T cells can not only serve as a CAR-T screening marker, but also add a safety switch for clinical research. Related flow cytometry antibodies can be inquired ( iCARTab, CAT# IAB001A )